Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a global life sciences and diagnostics innovator whose news flow is closely followed by investors, healthcare professionals and industry observers. The company regularly issues press releases on its financial performance, capital allocation decisions and participation in major healthcare conferences, providing insight into how its life sciences and diagnostics businesses are performing and evolving.
On this page, readers can find news about Danaher’s quarterly and annual results, including updates on revenue trends, non‑GAAP core revenue growth and adjusted earnings, as described in its earnings releases and related Form 8‑K filings. The company frequently hosts earnings conference calls and webcasts, and it posts accompanying slide presentations, non‑GAAP reconciliations and notes on historical and anticipated financial performance in its investors materials.
Danaher also announces regular quarterly cash dividends on its common stock and discloses share repurchase authorizations, giving shareholders visibility into its capital allocation approach. In addition, news items cover leadership and governance developments, such as planned transitions in senior executive roles and changes in board composition, as documented in the company’s communications and SEC reports.
Beyond financial and corporate updates, Danaher’s news includes product and research announcements from its operating companies. For example, Beckman Coulter Diagnostics, a Danaher company, has reported the launch of a fully automated Brain‑derived Tau research use only immunoassay test and the development of an Aβ‑42 research use only immunoassay test to support neurodegenerative disease research. These stories illustrate how Danaher’s diagnostics businesses contribute to advanced clinical and research capabilities.
By reviewing the DHR news feed, users can monitor earnings announcements, dividend declarations, conference presentations, governance updates and scientific developments across Danaher’s life sciences and diagnostics platform. This page can be a useful resource for tracking how the company communicates its strategy, performance and innovation activities over time.
Danaher (NYSE: DHR) has announced a strategic partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize advanced diagnostic tools for precision medicine. The collaboration will leverage Danaher's Centers for Enabling Precision Medicine and technology from its subsidiary, Leica Biosystems, focusing initially on digital and computational pathology products with AI-assisted algorithms.
The partnership aims to create diagnostic tests that help identify patients most likely to benefit from targeted therapies. Leica Biosystems will utilize its global laboratory network to deploy these tests worldwide, supported by its commitment to open-access DICOM standards for enhanced workflow connectivity.
Aldevron and Integrated DNA Technologies (IDT), both Danaher (NYSE: DHR) subsidiaries, have achieved a groundbreaking milestone by manufacturing the world's first personalized CRISPR gene editing drug to treat an infant with urea cycle disorder (UCD). The therapy was developed in just six months, three times faster than standard timelines.
The treatment, created in collaboration with Children's Hospital of Philadelphia and the University of Pennsylvania, required a new guide RNA sequence, mRNA-encoded base editor, custom off-target safety services, and clinically validated lipid nanoparticle formulation. The results were published in The New England Journal of Medicine, demonstrating the potential for safe and effective personalized CRISPR therapies.
This achievement aligns with the Danaher-IGI Beacon for CRISPR Cures initiative launched in January 2024, which aims to develop platform approaches for gene-editing medicines targeting hundreds of diseases.
Danaher Corporation (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the Bank of America Securities Health Care Conference in Las Vegas on May 15, 2025 at 10:00 a.m. PT. The presentation will be available via simultaneous webcast on the company's website at www.danaher.com.
Danaher Corporation (NYSE: DHR) has declared a regular quarterly cash dividend of $0.32 per share of common stock. The dividend will be paid on July 25, 2025 to shareholders who are recorded as holders on June 27, 2025. This announcement represents the company's commitment to returning value to shareholders through consistent dividend payments.
Kytopen and Aldevron have announced a joint marketing agreement to enhance cell therapy manufacturing workflows. The collaboration combines Aldevron's Nanoplasmid vector technology with Kytopen's Flowfect Tx GMP platform for CRISPR-mediated T-cell engineering.
Key benefits of this partnership include:
- High transgene expression and improved safety from Nanoplasmid technology
- Gentle gene delivery with unlimited scale through Flowfect continuous flow technology
- Enhanced CRISPR-mediated T-cell engineering with higher yields
- Cost-effective and time-saving manufacturing process
The companies will present their joint findings at the International Society of Cell & Gene Therapy Annual Meeting in New Orleans (May 7-10, 2025). The presentation will showcase increased overall yield of final drug substance and easier manufacturing compared to viral and electroporation technologies.
Danaher (NYSE: DHR) has reported its Q1 2025 financial results, with net earnings of $1.0 billion ($1.32 per diluted share) and non-GAAP adjusted diluted earnings of $1.88 per share. Revenues saw a slight decrease of 1.0% to $5.7 billion, while non-GAAP core revenue remained flat year-over-year. The company generated strong cash flows with operating cash flow of $1.3 billion and non-GAAP free cash flow of $1.1 billion.
Looking ahead, Danaher expects low-single-digit core revenue growth for Q2 2025 and maintains its full-year 2025 core revenue growth projection of approximately 3%. The company has initiated full-year adjusted diluted earnings guidance of $7.60 to $7.75 per share.
Danaher (NYSE: DHR) has announced its upcoming first quarter 2025 earnings conference call, scheduled for Tuesday, April 22, 2025, at 8:00 a.m. ET. The hour-long presentation will include discussions on financial performance and future expectations.
The event will be accessible through a webcast on Danaher's website under the 'Investors' section, accompanied by slide presentations. Participants can join via phone by dialing 800-245-3047 (U.S.) or +1 203-518-9765 (international) using Conference ID: DHRQ125.
A replay will be available until May 6, 2025. The earnings press release, webcast slides, and related materials will be posted on Danaher's website at 6:00 a.m. ET on the day of the call.